Dark

Check out our Dark Pool Levels

XENT
Intersect ENT, Inc
stock NASDAQ

Inactive

May 12, 2022

28.24USD0.000%(0.00)837,170

Pre-market

0.00USD-100.000%(-28.24)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 25, 2022

07:41AM EST Intersect ENT: Real-world Data Support Use Of PROPEL In RTTNews

07:06AM EST Real-World Evidence Study Data Shows Intersect ENT's PROPEL Sinus Implant Reduces Healthcare Resource Utilization RTTNews

07:00AM EST Real-World Evidence Study Demonstrates Intersect ENT's PROPEL(r) Sinus Implant Reduces Healthcare Resource Utilization Business Wire

Nov 2, 2021

05:26PM EDT Intersect ENT Q3 EPS $(0.48) Down From $(0.34) YoY, Sales $24.40M Up From $22.72M YoY Benzinga

04:15PM EDT Intersect ENT Reports Third Quarter 2021 Financial Results Business Wire

Oct 28, 2021

07:37AM EDT Intersect ENT Announces First Implants Of PROPEL Contour In Patients With Chronic Rhinosinusitis Following Frontal Sinus Surgery In Europe Benzinga

07:01AM EDT First Implants of PROPEL(r) Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe Business Wire

Aug 12, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021 Benzinga

04:51AM EDT SVB Leerink Downgrades Intersect ENT to Market Perform, Announces $28.25 Price Target Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

05:10AM EDT BTIG Downgrades Intersect ENT to Neutral Benzinga

Aug 9, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 Benzinga

10:24AM EDT Canaccord Genuity Downgrades Intersect ENT to Hold, Lowers Price Target to $28.25 Benzinga

08:09AM EDT Guggenheim Downgrades Intersect ENT to Neutral, Announces $28.25 Price Target Benzinga

Aug 7, 2021

10:07AM EDT (XENT Alert) Johnson Fistel Investigates Proposed Sale of Intersect ENT; Is PR Newswire

Aug 6, 2021

06:41PM EDT INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT Business Wire

07:52AM EDT Intersect ENT: Q2 Earnings Insights Benzinga

07:22AM EDT Intersect ENT Q2 Adj. EPS $(0.49) Misses $(0.43) Estimate, Sales $27.30M Miss $28.02M Estimate Benzinga

07:21AM EDT Intersect ENT Q2 Loss Per Share $0.50; Adj Loss Per Share $0.49 RTTNews

07:15AM EDT Intersect ENT Reports Second Quarter 2021 Financial Results Business Wire

07:02AM EDT Medtronic To Acquire Intersect ENT For $28.25/Shr Cash RTTNews

07:01AM EDT Medtronic To Buy Intersect ENT For $28.25/Share In Cash Benzinga

07:00AM EDT Medtronic to Acquire Intersect ENT PR Newswire

04:22AM EDT Earnings Scheduled For August 6, 2021 Benzinga

Aug 5, 2021

11:10AM EDT A Preview Of Intersect ENT's Earnings Benzinga

Jul 26, 2021

07:00AM EDT U.S Nationwide Commercial Availability of the VenSure(tm) Balloon Sinus Dilation System and Cube(tm) Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis Business Wire

Jul 23, 2021

08:42AM EDT Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding Benzinga

08:00AM EDT Intersect ENT to Report Second Quarter 2021 Financial Results on August 6 Business Wire

Jul 22, 2021

04:59PM EDT Intersect ENT Announces Q2 Preliminary Revenues Of $27.3 Mln RTTNews

04:09PM EDT Intersect ENT Sees Q2 2021 Revs $27.3M Vs $28.02M Est Benzinga

04:05PM EDT Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan Business Wire

Jun 24, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021 Benzinga

07:14AM EDT SVB Leerink Upgrades Intersect ENT to Outperform, Raises Price Target to $23 Benzinga

Jun 23, 2021

10:48AM EDT Intersect ENT Insights: Return On Capital Employed Benzinga

Jun 7, 2021

09:12AM EDT Intersect ENT Chief Operating Officer Christine Kowalski Ceased To Be Officer And Employee Jun. 4 Benzinga

May 20, 2021

07:52AM EDT Intersect ENT Gets CE Mark Approval For PROPEL Contour For Chronic Rhinosinusitis Following Frontal Sinus Surgery RTTNews

07:48AM EDT Intersect ENT Receives CE Mark Approval For PROPEL Contour For Patients With Chronic Rhinosinusitis Following Frontal Sinus Surgery Benzinga

May 18, 2021

01:57PM EDT Piper Sandler On Intersect ENT Following PROPEL, PROPEL Mini CE Mark Suspensions Being Lifted: Does Not Expect Any Material Impact On Co.'s Financials For Q2, 'we see the company as well-positioned to deliver against this international target' Benzinga

01:20PM EDT Intersect Says Received Notification From Notified Body That Suspension Was Lifted Effective May 14, 2021 And Co May Continue To Use Its CE Marks Benzinga

May 11, 2021

12:55PM EDT SVB Leerink Maintains Market Perform on Intersect ENT, Lowers Price Target to $21 Benzinga

May 10, 2021

09:31AM EDT UPDATE: Intersect ENT Q1 Adj. EPS $(0.51) Misses $(0.42) Estimate Benzinga

08:21AM EDT Intersect ENT Q1 Net Loss $20.0 Mln Or $0.61/Shr Vs Loss $17.5 Mln Or $0.54/Shr Last Year RTTNews

08:03AM EDT Recap: Intersect ENT Q1 Earnings Benzinga

07:25AM EDT Intersect ENT Sees FY21 Revs $117M-$121M Vs $119.41M Est Benzinga

07:23AM EDT Intersect ENT Raises Guidance Benzinga

07:23AM EDT Intersect ENT Q1 EPS $(0.61) Misses $(0.42) Estimate, Sales $24.30M Beat $23.54M Estimate Benzinga

07:03AM EDT Intersect ENT Reports First Quarter 2021 Financial Results Business Wire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

04:05PM EDT Intersect ENT to Participate at Upcoming Investor Conferences Business Wire

May 4, 2021

07:00AM EDT Intersect ENT Announces Appointment of New Vice President of Sales Business Wire

Apr 29, 2021

04:05PM EDT Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement Business Wire

07:00AM EDT EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL(r) Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation Business Wire

Apr 20, 2021

08:00AM EDT Intersect ENT to Report First Quarter 2021 Financial Results Business Wire

Apr 5, 2021

04:05PM EDT Intersect ENT Announces Changes to its Board of Directors Business Wire

Mar 11, 2021

04:05PM EST Dr. Neil Hattangadi Joins Intersect ENT's Board of Directors Business Wire

Mar 10, 2021

08:30AM EST Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference Business Wire

05:36AM EST SVB Leerink Maintains Market Perform on Intersect ENT, Raises Price Target to $25 Benzinga

Mar 9, 2021

09:16AM EST Intersect ENT Q4 EPS $(0.54) Misses $(0.32) Estimate, Sales $28.20M Beat $27.92M Estimate Benzinga

09:16AM EST Intersect ENT Sees FY21 Sales $116M-$120M Vs. $119.62M Est. Benzinga

07:30AM EST Intersect ENT Q4 Net Loss $20.2 Mln Or $0.62/Shr Vs Loss $8.0 Mln Or $0.25/Shr Last Year RTTNews

07:00AM EST Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

04:09AM EST Earnings Scheduled For March 9, 2021 Benzinga

Mar 8, 2021

10:09AM EST A Preview Of Intersect ENT's Earnings Benzinga

07:00AM EST CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication Business Wire

Feb 23, 2021

04:05PM EST Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results Business Wire

Feb 11, 2021

07:00AM EST Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL(r) Mini Sinus Implant Business Wire

Feb 1, 2021

04:05PM EST Intersect ENT to Participate in Upcoming Investor Conferences Business Wire

Jan 19, 2021

07:06AM EST Intersect ENT Announces CMS Approval Of Coding Application For PROPEL Sinus Implant Benzinga

Jan 12, 2021

07:12AM EST Intersect ENT Sees Q4 Preliminary Revenue In Range Of $27.7 To $28.1 Mln RTTNews

07:08AM EST Intersect ENT Sees Q4 Prelim Sales $27.7M-$28.1M Vs. $27.67M Est. Benzinga

07:00AM EST Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020 Business Wire

Jan 11, 2021

10:06AM EST Benzinga's Top Upgrades, Downgrades For January 11, 2021 Benzinga

05:38AM EST Canaccord Genuity Upgrades Intersect ENT to Buy, Raises Price Target to $25 Benzinga

Jan 5, 2021

08:00AM EST CORRECTING and REPLACING - Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 17, 2020

04:05PM EST Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Nov 19, 2020

07:18AM EST BTIG Upgrades Intersect ENT to Buy, Announces $32 Price Target Benzinga

Nov 17, 2020

04:45PM EST Intersect ENT Announces New Appointments to Executive Leadership Team Business Wire

Nov 5, 2020

04:06PM EST Intersect ENT to Participate at Upcoming Investor Conferences Business Wire

Nov 3, 2020

04:05AM EST SVB Leerink Maintains Market Perform on Intersect ENT, Lowers Price Target to $18 Benzinga

Nov 2, 2020

08:26AM EST Intersect ENT: Q3 Earnings Insights Benzinga

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

07:14AM EST Intersect ENT Q3 Revenue Of $22.7 Mln Up From $24.1 Mln Prior Year RTTNews

07:03AM EST Intersect ENT Q3 EPS $(0.35) Beats $(0.45) Estimate, Sales $22.70M Beat $21.37M Estimate Benzinga

07:00AM EST Intersect ENT Reports Third Quarter 2020 Financial Results Business Wire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 15, 2020

04:06PM EDT Intersect ENT Sees Q3 Sales $22.4M-$22.8M Vs. $21.37M Est. Benzinga

04:05PM EDT Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020 Business Wire

Oct 9, 2020

08:00AM EDT Intersect ENT to Report Third Quarter 2020 Financial Results Business Wire

Oct 8, 2020

10:00AM EDT Benzinga's Top Upgrades, Downgrades For October 8, 2020 Benzinga

06:09AM EDT JP Morgan Downgrades Intersect ENT to Neutral, Announces $19 Price Target Benzinga

Oct 2, 2020

08:05AM EDT Intersect ENT Closes Acquisition Of Fiagon AG Medical Technologies For EUR 60 Mln Cash RTTNews

08:00AM EDT Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies Business Wire

Sep 15, 2020

08:17AM EDT Intersect ENT To Acquire Fiagon AG Medical Technologies For EUR 60 Mln RTTNews

08:02AM EDT Intersect ENT Announces Agreement To Acquire Fiagon AG Medical Technologies For 60M Paid Over Three Years Benzinga

08:00AM EDT Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for (euro)60 Million Paid Over Three Years Business Wire

Sep 10, 2020

05:32PM EDT Intersect ENT Announces Specialty Pharmacy Partnership Agreement With AllianceRx Walgreens Prime To Distribute SINUVA Sinus Implant Benzinga

Aug 5, 2020

10:13AM EDT SVB Leerink Maintains Market Perform on Intersect ENT, Raises Price Target to $19.5 Benzinga

Aug 4, 2020

07:19AM EDT Intersect ENT Q2 Adj. EPS $(0.65) Misses $(0.56) Estimate, Sales $9.78M Beat $5.41M Estimate Benzinga

07:14AM EDT Intersect ENT Q2 Net Loss $23.1 Or $0.71/shr Vs. Net Loss $11.4 Mln Or $0.36/shr Last Year RTTNews

07:00AM EDT Intersect ENT Reports Second Quarter 2020 Financial Results Business Wire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 22, 2020

04:05PM EDT Intersect ENT to Report Second Quarter 2020 Financial Results Business Wire

Jul 15, 2020

07:13AM EDT SVB Leerink Maintains Market Perform on Intersect ENT, Raises Price Target to $18.5 Benzinga

Share